AdvanCell

AdvanCell is an Australian radiopharmaceutical company developing next-generation cancer treatments called Targeted Alpha Therapies. These therapies harness the natural decay and radiochemical properties of certain elements, combined with specific targeting molecules, to selectively deliver cell-killing radiation to tumor cells. AdvanCell's proprietary platform technology is a world-first alpha isotope generator that addresses the critical unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotopes. The company has developed a scalable manufacturing platform to produce alpha-emitting isotopes, particularly Lead-212 (212Pb), for research, preclinical, and clinical use, advancing its own and partners' radiopharmaceutical products.

AdvanCell's lead clinical program, 212Pb-ADVC001, a Targeted Alpha Therapy for treating metastatic castration-resistant prostate cancer, dosed its first patient in November 2023. As of November 2020, the company developed the world's first 212Pb-based Targeted Alpha Therapy to enter clinical trials for metastatic prostate cancer. Additionally, AdvanCell has a proprietary target discovery and ligand development program encompassing a robust pipeline of Targeted Alpha Therapies for treating various cancers.

In August 2022, AdvanCell closed an AUSD 18 million Series B funding round led by Morningside. The company has raised USUSD 13 million from world-class investors and received USD 10 million in non-dilutive grant funding. In June 2023, AdvanCell signed a letter of intent with POINT Biopharma to collaborate on developing a global 212Pb radioisotope and radioligand supply chain and drug manufacturing network. AdvanCell was acquired by an undisclosed company in January 2024.